CMPR Readiness: A Four-Tier Checklist ahead of the 2026 Legislation

1. Key takeaways

The Hong Kong Centre for Medical Products Regulation (CMPR) is intended to be established by the end of 2026, and the government plans to submit legislative proposals on the regulation of medical devices to the Legislative Council in 2026. Once legislation is in place, all medical devices supplied in Hong Kong, China must be registered unless exempt. For companies, the transition leaves a window of the order of 12 months (practical estimate, subject to official announcement). The readiness checklist is organised into 4 tiers by priority: act now (listing and the local entity), run in parallel (organising the evidence base), prepare ahead (vigilance and record systems) and sustain (tracking the legislation).

• The phrase unless exempt signals an expansion of coverage, not a continuation of the present scope.
• The preparatory office will absorb functions and staff from the units currently handling western medicines, Chinese medicines and medical devices, so the interface, forms and numbering may change as a set.
• The bill must pass through the Legislative Council before any legal requirement exists; the submission date is a milestone, not an effective date.
• Listing today is the most cost-effective action available in the transition, because it builds three assets at once: a local entity, a technical file and a post-market record.
• Products that are outside MDACS today are the ones most exposed, because nothing in their current file has been prepared for a registration system.

2. Legal basis

The policy position is recorded in Legislative Council papers, government press releases and a policy document on the establishment of the centre. Regulatory information was verified as of 29 October 2026; if an official document has since been updated, the latest published version prevails.

Read together, the documents describe a sequence rather than a single event: a centre established within 2026, a bill submitted in 2026, first-tier evaluation implemented in phases, and registration required after legislation. Each step has its own date, and the compliance consequence attaches to the last of them. Planning against the earliest date produces readiness; planning against the last produces a scramble.

3. Expert insights

Insight one: registration required unless exempt means an expansion of coverage. MDACS currently covers Class II and above. After the legislation takes effect, coverage may extend to all devices. Class I general medical devices and Class A in vitro diagnostic medical devices, which are not currently caught, should be placed on the future compliance list. The risk for these products is not the cost of registration but the absence of preparation: a Class I product often has a thinner technical file than a higher-class device, and a thinner file takes longer to bring up to standard than a well-developed one.

Insight two: the integration of the preparatory office will bring process reconstruction. The government has stated that the functions and staffing of the Department of Health service units currently responsible for western medicines, Chinese medicines and medical devices will be integrated into the CMPR. The interface, the form system and the numbering rules may all be replaced as a set, and companies should allow room for system rework. The practical exposure is in the identifiers: an internal database keyed to a current application number, or a quality system that cites a current form number, will need mapping work that is easier to plan than to improvise.

Insight three: the bill goes to the Legislative Council first, and the law comes afterwards. The policy document explains that the bill on medical device regulation is being prepared and is intended for submission to the Legislative Council in 2026 after consultation with the industry and relevant stakeholders. From submission to passage and then to commencement there are several procedural steps, and companies should follow each of them rather than watching only the single milestone of submission in 2026. A submission date tells you when the drafting is finished; it does not tell you when the obligation begins.

Insight four: listing is the most cost-effective action in the transition period. The government has repeatedly encouraged the industry to list under MDACS as early as possible, in preparation for the transition to the future statutory framework. A company that is already listed holds three assets: an established local entity, an established technical file and an established post-market record. Each of the three would have to be created from nothing under a statutory regime, and each takes longer to build than to update.

Insight five: the local entity decision is the one that cannot be deferred. Legal, contractual and staffing arrangements for a local responsible person take time to put in place, and they constrain everything filed afterwards. Where the entity is not yet established the listing cannot begin, and the transition window is consumed by an administrative step rather than technical work, which is why the first tier places the two together.

4. Practical recommendations

Tier one (act now, 0–3 months)

• 1. Complete the listing of products intended for long-term sale in Hong Kong, China; 2. Identify and secure the LRP entity; 3. For injection and infusion products, schedule backwards from 1 March 2027.

Tier two (run in parallel, 3–6 months)

• 4. Restructure the technical file to the IMDRF common structure; 5. Review the scope of the quality system certificate and the standard versions (RS-01); 6. Establish a standard version register.

Tier three (prepare ahead, 6–12 months)

• 7. Build the vigilance and record system; 8. Complete the compliance assessment for lower-class devices (Class I and Class A); 9. Write a regulatory change clause into the LRP contract.

Tier four (sustain)

• 10. Track Legislative Council Panel on Health Services papers and Department of Health press releases quarterly; 11. Subscribe to the MDD developments page; 12. Update the verification date of the articles in this series.

5. Verification checklist

• □ The target establishment date of the CMPR, the end of 2026, is recorded
• □ The official statement on submission of legislative proposals in 2026 is recorded
• □ Listing of long-term sale products has started or been completed
• □ The LRP entity is confirmed and a regulatory change clause is included in the contract
• □ Injection and infusion products have been scheduled backwards from 1 March 2027
• □ The technical file has been restructured to the common structure
• □ A future compliance list for lower-class devices has been created
• □ The vigilance and record system has been built
• □ A legislative tracking mechanism is in place with quarterly review
• □ The transition window estimate has been re-checked against the latest official announcement

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages adverse incident reporting and recall coordination with the Department of Health, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com